Enalapril. An Update of Its Pharmacological Properties and Therapeutic Use in Congestive Heart Failure

Overview

Journal Drugs

Specialty Pharmacology

Date 1989 Feb 1

PMID 2539290

Citations 10

Authors

P A Todd

K L Goa

Affiliations

Soon will be listed here.

Abstract

Enalapril provides significant haemodynamic, symptomatic and clinical improvement when added to maintenance therapy with digitalis and diuretics in patients with congestive heart failure [NYHA (New York Heart Association) classes II to IV]. These effects are not attenuated during long term therapy. More significantly, a clinical study demonstrated that enalapril reduces mortality when added to established therapy in patients with severe congestive heart failure (NYHA class IV) refractory to digitalis, diuretics and other vasodilators. Thus, ACE inhibitors such as enalapril offer a significant advance in the treatment of congestive heart failure. Because these drugs improve symptoms in patients with classes II to IV failure, and reduce mortality in patients with severe heart failure, they should be considered as first choice adjuvant therapy when a vasodilator is needed in addition to conventional treatment with digitalis and diuretics.

Citing Articles

Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension.

Siddiqui M, Plosker G Drugs. 2004; 64(10):1135-48.

PMID: 15139792 DOI: 10.2165/00003495-200464100-00009.

Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Wilde M, Bryson H, Goa K Pharmacoeconomics. 1994; 6(2):155-82.

PMID: 10147441 DOI: 10.2165/00019053-199406020-00008.

Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Hoyer J, Schulte K, Lenz T Clin Pharmacokinet. 1993; 24(3):230-54.

PMID: 8462229 DOI: 10.2165/00003088-199324030-00005.

Perindopril. A review of its pharmacokinetics and clinical pharmacology.

MacFadyen R, Lees K, Reid J Drugs. 1990; 39 Suppl 1:49-63.

PMID: 2407493 DOI: 10.2165/00003495-199000391-00009.

Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.

Thind G Cardiovasc Drugs Ther. 1990; 4(1):199-206.

PMID: 2285612 DOI: 10.1007/BF01857634.

References

Dickstein K, Till A, Aarsland T, Tjelta K, Abrahamsen A, Kristianson K . The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Br J Clin Pharmacol. 1987; 23(4):403-10. PMC: 1386089. DOI: 10.1111/j.1365-2125.1987.tb03069.x. View

Lancaster S, Todd P . Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988; 35(6):646-69. DOI: 10.2165/00003495-198835060-00003. View

Packer M, Lee W, Yushak M, Medina N . Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986; 315(14):847-53. DOI: 10.1056/NEJM198610023151402. View

Nicholls M, Gilchrist N . Sulindac and cough induced by converting enzyme inhibitors. Lancet. 1987; 1(8537):872. DOI: 10.1016/s0140-6736(87)91663-1. View

Joy M, Hubner P, Thomas R, Cummin P, Dews I, Williams H . Long term use of enalapril in the treatment of patients with congestive heart failure. Int J Cardiol. 1987; 16(2):137-44. DOI: 10.1016/0167-5273(87)90244-0. View

Packer M, Lee W, Kessler P, Medina N, Yushak M, Gottlieb S . Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol. 1987; 10(4):837-44. DOI: 10.1016/s0735-1097(87)80278-4. View

Coulter D, Edwards I . Cough associated with captopril and enalapril. Br Med J (Clin Res Ed). 1987; 294(6586):1521-3. PMC: 1246673. DOI: 10.1136/bmj.294.6586.1521. View

Packer M, Lee W, Medina N, Yushak M, Kessler P, Gottlieb S . Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med. 1987; 82(6):1119-26. DOI: 10.1016/0002-9343(87)90213-0. View

Johnston C, Jackson B, McGrath B, Matthews G, Arnolda L . Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. J Hypertens Suppl. 1983; 1(1):71-5. View

10.

Bounhoure J . [Treatment of cardiac failure with enalapril]. Presse Med. 1985; 14(44):2215-7. View

11.

Hess B, Keusch G, Neftel K, Margelist F, Bansky G . [Severe electrolyte disorders during the therapy of heart failure with the therapy of heart failure with the ACE-inhibitor enalapril]. Schweiz Med Wochenschr. 1986; 116(39):1331-6. View

12.

Lees K, Reid J . Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther. 1987; 41(6):597-602. DOI: 10.1038/clpt.1987.81. View

13.

Romankiewicz J, Brogden R, Heel R, Speight T, Avery G . Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs. 1983; 25(1):6-40. DOI: 10.2165/00003495-198325010-00002. View

14.

Furberg C, Yusuf S . Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol. 1988; 62(2):41A-45A. DOI: 10.1016/s0002-9149(88)80084-5. View

15.

Waeber B, Nussberger J, Brunner H . Self poisoning with enalapril. Br Med J (Clin Res Ed). 1984; 288(6413):287-8. PMC: 1444051. DOI: 10.1136/bmj.288.6413.287. View

16.

Kromer E, Riegger G, LIEBAU G, Kochsiek K . Effectiveness of converting enzyme inhibition (enalapril) for mild congestive heart failure. Am J Cardiol. 1986; 57(6):459-62. DOI: 10.1016/0002-9149(86)90772-1. View

17.

Sweet C, LUDDEN C, Stabilito I, Emmert S, Heyse J . Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. Eur J Pharmacol. 1988; 147(1):29-37. DOI: 10.1016/0014-2999(88)90630-9. View

18.

Lindgren B, Anderson C, Andersson R . Potentiation of inflammatory reactions in guinea-pig skin by an angiotensin converting enzyme inhibitor (MK 422). Eur J Pharmacol. 1987; 135(3):383-7. DOI: 10.1016/0014-2999(87)90688-1. View

19.

ONeill C, Bowes S, Sullens C, Royston J, Hunt W, Denham M . Evaluation of the safety of enalapril in the treatment of heart failure in the very old. Eur J Clin Pharmacol. 1988; 35(2):143-50. DOI: 10.1007/BF00609243. View

20.

Furberg C, Yusuf S . Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol. 1985; 55(8):1110-3. DOI: 10.1016/0002-9149(85)90756-8. View